Articles / New opioid restrictions now in place
writer
Associate Professor and Deputy Director, Monash Addiction Research Centre, Monash University
0 hours
These are activities that expand general practice knowledge, skills and attitudes, related to your scope of practice.
0 hours
These are activities that require reflection on feedback about your work.
0 hours
These are activities that use your work data to ensure quality results.
These are activities that expand general practice knowledge, skills and attitudes, related to your scope of practice.
These are activities that require reflection on feedback about your work.
These are activities that use your work data to ensure quality results.
Several changes to the regulation of opioid supply in Australia come into effect today (June 1).
Opioids are strong medicines used for pain. The new rules – including reducing pack sizes and restrictions around prescribing – are part of a range of changes planned for prescription opioid medicines to be phased in over the next year or so.
This comes in response to the to the growing number of deaths involving opioids in Australia. From 2007 to 2016, opioid-related deaths nearly doubled – from 591 to 1,119 deaths per year.
Notably, most of these deaths involve prescription opioids used for pain, rather than illicit opioids like heroin.
Menopausal Hormone Therapy - What Dose of Estrogen is Best?
Cardiovascular Benefits of GLP1s – New Evidence
Oral Contraceptive Pill in Teens
RSV and the Heart
writer
Associate Professor and Deputy Director, Monash Addiction Research Centre, Monash University
Modified but kept in place
Eliminated entirely without replacement
Maintained as is
Completely replaced with an alternative system
Listen to expert interviews.
Click to open in a new tab
Browse the latest articles from Healthed.
Once you confirm you’ve read this article you can complete a Patient Case Review to earn 0.5 hours CPD in the Reviewing Performance (RP) category.
Select ‘Confirm & learn‘ when you have read this article in its entirety and you will be taken to begin your Patient Case Review.
Menopause and MHT
Multiple sclerosis vs antibody disease
Using SGLT2 to reduce cardiovascular death in T2D
Peripheral arterial disease